Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Karjalainen, Jussi
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP	Active, not recruiting	3	1667	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	10/25	10/25
NCT03718793: Small Airway Inflammation and Dysfunction in Different Asthma Phenotypes	Recruiting	N/A	160	Europe	Peripheral exhaled nitric oxide, Impulse oscillometry, ECP/B-eos ratio	Tampere University Hospital	Asthma	12/24	12/24
NCT05740163: Oral Immunotherapy for Egg Allergy in Children Aged 6 to 16	Recruiting	N/A	60	Europe	Egg product including egg white and yolk allergens	Tampere University Hospital, University of Oulu, Oulu University Hospital	Egg Allergy	12/24	12/26